Blood Reviews
Volume 22 , Pages S14-S21 , December 2008

Cardiac iron across different transfusion-dependent diseases

  • John C. Wood

      Affiliations

    • Corresponding Author InformationJohn C. Wood, MD, PhD. Division of Cardiology, Mailstop 34, Children's Hospital Los Angeles, 4650 Sunset Blvd, Los Angeles, CA 90027, USA. Tel: 323 361 5450; Fax: 323 361 7317

References 

  1. Olivieri NF , Nathan DG , MacMillan JH , et al.   Survival in medically treated patients with homozygous beta-thalassemia . N Engl J Med . 1994;331:574–578
  2. Borgna-Pignatti C , Rugolotto S , De SP , et al.   Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine . Haematologica . 2004;89:1187–1193
  3. Buja LM , Roberts WC . Iron in the heart. Etiology and clinical significance . Am J Med . 1971;51:209–221
  4. Wood JC , Enriquez C , Ghugre N , et al.   Physiology and pathophysiology of iron cardiomyopathy in thalassemia . Ann NY Acad Sci . 2005;1054:386–395
  5. Oudit GY , Trivieri MG , Khaper N , et al.   Role of L-type Ca2+ channels in iron transport and iron-overloaded cardiomyopathy . J Mol Med . 2006;84:349–364
  6. Bartfay WJ , Bartfay E . Iron-overload cardiomyopathy: evidence for a free radical-mediated mechanism of injury and dysfunction in a murine model . Biol Res Nurs . 2000;2:49–59
  7. Gabutti V , Piga A . Results of long-term iron-chelating therapy . Acta Haematol . 1996;95:26–36
  8. Telfer PT , Prestcott E , Holden S , et al.   Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major . Br J Haematol . 2000;110:971–977
  9. Davis BA , O'Sullivan C , Jarritt PH , et al.   Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major . Blood . 2004;104:263–269
  10. Brittenham GM , Griffith PM , Nienhuis AW , et al.   Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassaemia major . N Engl J Med . 1994;331:567–573
  11. Angelucci E , Brittenham GM , McLaren CE , et al.   Hepatic iron concentration and total body iron stores in thalassemia major . N Engl J Med . 2000;343:327–331
  12. Angelucci E , Baronciani D , Lucarelli G , et al.   Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies . Br J Haematol . 1995;89:757–761
  13. St Pierre TG , Clark PR , Chua-Anusorn W , et al.   Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance . Blood . 2005;105:855–861
  14. Wood JC . Diagnosis and management of transfusion iron overload: the role of imaging . Am J Hematol . 2007;82(12 Suppl):1132–1135
  15. Wood JC , Ghugre N . Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases . Hemoglobin . 2008;32:85–96
  16. Anderson LJ , Holden S , Davis B , et al.   Cardiovascular T2- star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload . Eur Heart J . 2001;22:2171–2179
  17. Porter JB . Practical management of iron overload . Br J Haematol . 2001;115:239–252
  18. Wood JC . Magnetic resonance imaging measurement of iron overload . Curr Opin Hematol . 2007;14:183–190
  19. Wood JC , Otto-Duessel M , Aguilar M , et al.   Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy . Circulation . 2005;112:535–545
  20. Ghugre NR , Enriquez CM , Gonzalez I , et al.   MRI detects myocardial iron in the human heart . Magn Reson Med . 2006;56:681–686
  21. Cheung YF , Chan GC , Ha SY . Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major . Br J Haematol . 2008;141:728–733
  22. Li W , Coates T , Wood JC . Atrial dysfunction as a marker of iron cardiotoxicity in thalassemia major . Haematologica . 2008;93:311–312
  23. Tanner MA , Galanello R , Dessi C , et al.   A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance . Circulation . 2007;115:1876–1884
  24. Jensen PD , Jensen FT , Christensen T , et al.   Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool . Blood . 2003;101:4632–4639
  25. Schafer AAI , Cheron RG , Dluhy R , et al.   Clinical consequences of acquired transfusional iron overload in adults . N Engl J Med . 1981;304:319–324
  26. Borgna-Pignatti C , Cappellini MD , De Stefano P , et al.   Cardiac morbidity and mortality in desferrioxamine or deferiprone treated patients with thalassaemia major . Blood . 2006;107:3733–3737
  27. Wood JC , Tyszka JM , Carson S , et al.   Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease . Blood . 2004;103:1934–1936
  28. Wood JC , Origa R , Agus A , et al.   Onset of cardiac iron loading in pediatric patients with thalassemia major . Haematologica . 2008;93:917–920
  29. Glanville J , Eleftheriou P , Porter JB . MRI evidence of cardiac iron accumulation in myelodysplasia and unusual anaemias . Blood . 2006;108: abstract 1553.
  30. Chacko J , Pennell DJ , Tanner MA , et al.   Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions . Br J Haematol . 2007;138:587–593
  31. Konen E , Ghoti H , Goitein O , et al.   No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique . Am J Hematol . 2007;82:1013–1016
  32. Walter PB , Fung EB , Killilea DW , et al.   Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease . Br J Haematol . 2006;135:254–263
  33. Shah FT , Westwood MA , Evans PJ , et al.   Discordance in MRI assessment in iron distribution and plasma NTBI between transfusionally iron loaded adults with sickle cell and thalassemia . Blood . 2002;100: abstract 668a.
  34. Papanikolaou G , Tzilianos M , Christakis JI , et al.   Hepcidin in iron overload disorders . Blood . 2005;105:4103–4105
  35. Fung EB , Harmatz PR , Lee PD , et al.   Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease . Br J Haematol . 2006;135:574–582
  36. Smiley D , Dagogo-Jack S , Umpierrez G . Therapy insight: metabolic and endocrine disorders in sickle cell disease . Nat Clin Pract Endocrinol Metab . 2008;4:102–109
  37. Raman SV , Simonetti OP , Cataland SR , et al.   Myocardial ischemia and right ventricular dysfunction in adult patients with sickle cell disease . Haematologica . 2006;91:1329–1335
  38. Westwood MA , Shah F , Anderson LJ , et al.   Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathy . J Magn Reson Imaging . 2007;26:564–568
  39. Anderson LJ , Wonke B , Prescott E , et al.   Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia . Lancet . 2002;360:516–520
  40. Pennell DJ , Berdoukas V , Karagiorga M , et al.   Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis . Blood . 2006;107:3738–3744
  41. Glickstein H , El RB , Link G , et al.   Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences . Blood . 2006;108:3195–3203
  42. Wood JC , Otto-Duessel M , Gonzalez I , et al.   Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil . Transl Res . 2006;148:272–280
  43. Otto-Duessel M , Aguilar M , Nick H , et al.   Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy . Exp Hematol . 2007;35:1069–1073
  44. Vichinsky E , Onyekwere O , Porter J , et al.   A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease . Br J Haematol . 2007;136:501–508
  45. Piga A , Galanello R , Forni GL , et al.   Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload . Haematologica . 2006;91:873–880
  46. Cappellini MD , Cohen A , Piga A , et al.   A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia . Blood . 2006;107:3455–3462
  47. Porter J , Galanello R , Saglio G , et al.   Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study . Eur J Haematol . 2008;80:168–176
  48. Porter JB , Tanner MA , Pennell DJ , et al.   Improved myocardial T2* in transfusion dependent anemias receiving ICL670 (deferasirox) . Blood . 2005;106: abstract 3600.
  49. Wood J , Thompson AA , Paley C , et al.   MRI t2* demonstrates reduced cardiac iron burden following moderate-to high-dose deferasirox treatment in chronically transfused beta-thalassemia patients . Haematologica . 2008;93(1): abstract 0844.
  50. Taher A , Al Jefri A , Elalfy MS , et al.   Oral deferasirox (Exjade®, ICL670) is effective, with a clinically manageable safety profile, in pediatric β-thalassemia patients with high iron burden . Blood . 2007;110: abstract 2279.

PII: S0268-960X(08)70004-3

doi: 10.1016/S0268-960X(08)70004-3

Blood Reviews
Volume 22 , Pages S14-S21 , December 2008

Article Tools